Value
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 1.6 |
| P/S | 9.2 |
| EV/EBITDA | 4.1 |
| Fwd P/E | 7.1 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 17.6x
- ▸PEG: 0.14
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
| Pillar | Expectation | Trend |
|---|---|---|
Envista beaten EPS estimates by 15% or more in each of the last 4 quarters, with an average positive surprise of 15.6%, indicating that management is consistently delivering results materially ahead of what analysts model. Catalyst breakdown | EPS surprise remains above 10% in at least 3 of the next 4 quarters, maintaining the beat pattern at a meaningful margin. | →Stable |
| CounterConsistent 15% beats could reflect management guiding analyst expectations very conservatively rather than genuine operational outperformance, which would be a less durable tailwind. | ||
Envista converts 320% of net income to free cash flow, reflecting excellent working capital management and low capital expenditure requirements relative to reported earnings, which provides financial flexibility for debt reduction or shareholder returns. Quality breakdown | Free cash flow conversion remains above 150% of net income for the next 4 quarters, confirming the cash generation quality is durable. | →Stable |
| CounterFree cash flow conversion of 320% may temporarily spike from deferred capex or favorable working capital timing that reverses in future quarters, overstating the sustainable quality of earnings. | ||
51% of revenue is concentrated in North America, and this geographic concentration is flagged as a high concentration risk in the company's own filings, leaving the business exposed to North American demand cycles and regulatory shifts. Bear case | International revenue grows to represent at least 55% of total revenue within 12 months, reducing the single-region concentration below 45%. | →Stable |
| CounterNorth America is a stable, high-margin market for dental and medical instrument products, and domestic revenue concentration is not inherently more risky than global diversification when the home market is the largest and most profitable. | ||
The company relies on sole or limited source suppliers for critical inputs, which creates operational risk if any single supplier experiences disruption, potentially delaying product delivery and damaging customer relationships. Bear case | The company announces diversification of at least 1 critical sole-source supply relationship, reducing the number of sole-source dependencies by at least 20%. | →Stable |
| CounterSole-source supplier relationships in medical devices are common and often locked in by regulatory approval requirements, meaning the risk is well-understood and managed through contractual protections and safety stock. | ||
CounterConsistent 15% beats could reflect management guiding analyst expectations very conservatively rather than genuine operational outperformance, which would be a less durable tailwind.
CounterFree cash flow conversion of 320% may temporarily spike from deferred capex or favorable working capital timing that reverses in future quarters, overstating the sustainable quality of earnings.
CounterNorth America is a stable, high-margin market for dental and medical instrument products, and domestic revenue concentration is not inherently more risky than global diversification when the home market is the largest and most profitable.
CounterSole-source supplier relationships in medical devices are common and often locked in by regulatory approval requirements, meaning the risk is well-understood and managed through contractual protections and safety stock.
Envista Holdings has beaten earnings estimates in all 4 of the last quarters with an average positive surprise of 15.6%, generates free cash flow at 320% of net income, and carries a perfect Piotroski F-Score of 9/9, though geographic concentration in North America and thin price-to-upside margin limit immediate re-entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Component | Sub-score |
|---|---|
| P/E | 1.6 |
| P/S | 9.2 |
| EV/EBITDA | 4.1 |
| Fwd P/E | 7.1 |
| PEG | 10.0 |
| Analyst target | 4.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.7 |
| ROA | 2.0 |
| Gross margin | 7.1 |
| Op margin | 3.9 |
| Net margin | 1.2 |
| Current ratio | 8.3 |
| FCF quality | 10.0 |
| Moat | 7.1 |
| Piotroski F | 10.0 |
| Component | Sub-score |
|---|---|
| Rev growth | 6.1 |
| EPS growth | 10.0 |
| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.3 |
| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 6.1 |
| erm sentiment | 5.0 |
| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
| Component | Sub-score |
|---|---|
| value rank | 4.9 |
| quality rank | 4.6 |
| growth rank | 6.7 |
| Component | Sub-score |
|---|---|
| bollinger | 0.8 |
| support resistance | 0.0 |
| 52w position | 8.2 |
| gap | 5.0 |
| Component | Sub-score |
|---|---|
| short interest | 5.8 |
| days to cover | 7.1 |
| volatility | 5.0 |
| put call | 10.0 |
| implied vol | 6.0 |
| beta | 7.8 |
| debt equity | 7.9 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
Maintain position. Not compelling to add more.
L4:PATH_F_HOLDSetup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $4.5B<$5B
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.9>=5.5. Top dim: Growth at 8.1; weakest: Technical at 3.5. No conviction either direction.
The strongest dimensions are Growth at 8.1, Catalyst at 7.5, and Risk (lower is worse) at 7.1; the weakest are Technical at 3.5, Peer rank at 4.0, and Insider at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.43 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifEPS surprise falls below 5% in at least 2 of the next 4 quarters, signaling the beat streak is narrowing.
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive quarters.
Trip ifNorth America revenue concentration rises above 60% of total revenue in any reported quarter.
Trip ifA sole-source supplier disruption results in product shipment delays exceeding 30 days for any major product line, as disclosed in a quarterly filing.